Cargando…

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1

Background: Although nitisinone is successfully used to treat hereditary tyrosinemia type 1 (HT-1) with the recommended twice-daily dosing, data describing a long half-life motivate less frequent dosing. Therefore, in agreement with the Pharmacovigilance Risk Assessment Committee at the European Med...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guffon, Nathalie, Bröijersén, Anders, Palmgren, Ingrid, Rudebeck, Mattias, Olsson, Birgitta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874213/ https://www.ncbi.nlm.nih.gov/pubmed/28643275 http://dx.doi.org/10.1007/8904_2017_29

Ejemplares similares

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017)

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation
por: Colemonts-Vroninks, Haaike, et al.
Publicado: (2020)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
por: García, María Ignacia, et al.
Publicado: (2017)

Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways
por: Haaike, Colemonts-Vroninks, et al.
Publicado: (2022)

Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
por: Jack, Rhona M., et al.
Publicado: (2019)

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review
por: Geppert, Julia, et al.
Publicado: (2017)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts
Publicado: (1985)

Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia
por: Sarodaya, Neha, et al.
Publicado: (2020)

Revisiting hereditary tyrosinemia Type 1—spectrum of radiological findings
por: Shaikh, Sana, et al.
Publicado: (2018)

Hereditary Tyrosinemia Type 1 in Jordan: A Retrospective Study
por: Megdadi, Noor A., et al.
Publicado: (2021)

Inter‐laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples
por: Laeremans, Hilde, et al.
Publicado: (2020)

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
por: Ranganath, L.R., et al.
Publicado: (2022)

Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I
por: Gil-Martínez, Jon, et al.
Publicado: (2021)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1
por: Li, Li, et al.
Publicado: (2017)

Phenotype, genotype, and outcome of 25 Palestinian patients with hereditary tyrosinemia type 1
por: Dweikat, Imad, et al.
Publicado: (2021)

Hereditary Tyrosinemia Compounded With Hyperinsulinemic Hypoglycemia: Challenging Diagnosis of a Rare Case
por: Nasir, Sharmeen, et al.
Publicado: (2020)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

The Discovery of the Mode of Action of Nitisinone
por: Lock, Edward A.
Publicado: (2022)

Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era
por: Imseis, Essam M, et al.
Publicado: (2017)

Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver
por: Ren, Jilong, et al.
Publicado: (2022)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I
por: Angileri, Francesca, et al.
Publicado: (2014)

Experience of a Single Center in NTBC Use in Management of Hereditary Tyrosinemia Type I in Libya
por: Alobaidy, Hanna, et al.
Publicado: (2015)

Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia
por: Hendrikse, Natalie M., et al.
Publicado: (2020)

Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review
por: Daou, Karim N., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5hvuohftgc13em0mj9549scbqh